20 completed, 4 unknown, 2 recruiting, 1 withdrawn. 27 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Completed 20, Unknown 4, Recruiting 2, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Unknown 1 |
Follow Vulvitis: new trials by email Literature Review of Vulvitis trials Research Report on Vulvitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis Boric acid, Placebo - Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital | Phase 3 | Completed | pH-D Feminine Health LLC | 333 | 2025-08-08 | 2026-10-23 |
| Postbiotic as Adjunct Treatment for Vaginal Candidiasis Postbiotic, Placebo - Vaginal Candidiasis | Phase 2 / Phase 3 | Completed | Min-Tze LIONG | 99 | 2024-06-02 | 2026-07-07 |
| Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis Clotrimazole+Lactulose., Canesten (Clotrimazole), Lactulose - Candidal Vulvovaginitis (ICD-10 Code: B37.3), Vulvovaginal Candidiasis (VVC) | Phase 2 / Phase 3 | Recruiting | AVVA Pharmaceuticals Ltd. | 264 | 2024-02-29 | 2025-02-19 |
| Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories, Lactulose 300 mg vaginal suppositories, Pimafucin® (natamycin) 100 mg vaginal suppositories - Vulvovaginal Candidiasis, Genital | Phase 3 | Completed | Avva Rus, JSC | 218 | 2022-12-29 | 2024-05-13 |
| The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms Fluconazole, L-Mesitran - Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina | Phase 3 | Recruiting | Maastricht University Medical Center | 252 | 2022-08-22 | 2023-05-17 |
| Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis Ibrexafungerp - Vulvovaginal Candidiasis | Phase 3 | Completed | Scynexis, Inc. | 150 | 2022-05-01 | 2024-07-10 |
| A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis SHR8008, Fluconazole - Recurrent Vulvovaginal Candidiasis | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 196 | 2021-09-14 | 2021-10-12 |
| Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule EVEGYN A, EVEGYN B, Gynomax® XL Vaginal Ovule - Trichomonal Vaginitis, Bacterial Vaginosis | Phase 3 | Completed | Ege University | 577 | 2020-07-20 | 2023-09-28 |
| Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet - Recurrent Vulvovaginal Candidiasis | Phase 3 | Completed | Scynexis, Inc. | 440 | 2019-10-21 | 2023-06-18 |
| A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC) Prof-001, Fluconazole 150 mg, Placebo cream - Recurrent Vulvovaginal Candidiasis | Phase 2 / Phase 3 | Unknown | ProFem GmbH | 432 | 2019-10-01 | 2022-09-22 |
| Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Ibrexafungerp, Placebo - Candida Vulvovaginitis | Phase 3 | Completed | Scynexis, Inc. | 455 | 2019-06-07 | 2021-09-08 |
| Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule, Placebo - Recurrent Vulvovaginal Candidiasis | Phase 3 | Completed | Mycovia Pharmaceuticals Inc. | 219 | 2019-03-13 | 2022-02-04 |
| Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303) Ibrexafungerp, Placebo - Candida Vulvovaginitis | Phase 3 | Completed | Scynexis, Inc. | 376 | 2019-01-04 | 2021-09-08 |
| Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis LactiSal vaginal gel 1%, LactiSal vaginal tablet 50mg, Clotrimazole vaginal tablet 100mg - Vulvovaginal Candidiasis | Phase 3 | Withdrawn | Medinova AG | 2018-12-01 | 2019-03-08 | |
| A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Oteseconazole (VT-1161), Placebo - Recurrent Vulvovaginal Candidiasis | Phase 3 | Completed | Mycovia Pharmaceuticals Inc. | 425 | 2018-08-23 | 2026-02-17 |
| A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Oteseconazole (VT-1161), Placebo - Recurrent Vulvovaginal Candidiasis | Phase 3 | Completed | Mycovia Pharmaceuticals Inc. | 438 | 2018-08-16 | 2026-02-17 |
| Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis Ketoconazole, Terconazole - Vaginal Candidiasis | Phase 3 | Unknown | Assiut University | 69 | 2018-04-01 | 2018-03-22 |
| ProF-001_Phase IIa Candiplus, Clotrimazole - Vulvovaginal Candidiasis (VVC) | Phase 2 / Phase 3 | Completed | ProFem GmbH | 84 | 2017-04-04 | 2019-03-14 |
| Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Ibrexafungerp - Invasive Candidiasis, Mucocutaneous Candidiasis | Phase 3 | Completed | Scynexis, Inc. | 233 | 2017-04-01 | 2024-11-20 |
| Dysbiosis in Localized Provoked Vulvodynia (LPV) Low Oxalate Diet - Vulvodynia, Vulvar Vestibulitis | Phase 3 | Unknown | Western Galilee Hospital-Nahariya | 70 | 2015-03-01 | 2015-03-20 |
Showing 20 of 27. Sign in to see all of them.
Candidiasis, Vulvovaginal (25) · Vaginitis (3) · Vaginosis, Bacterial (3) · Vulvovaginitis (2) · Aspergillosis, Allergic Bronchopulmonary (1) · Blastomycosis (1) · Candidiasis (1) · Candidiasis, Chronic Mucocutaneous (1) · Candidiasis, Invasive (1) · Coccidioidomycosis (1) · Diabetes Mellitus (1) · Histoplasmosis (1) · Invasive Pulmonary Aspergillosis (1) · Mycoses (1) · Pruritus (1)
Female Urogenital Diseases (27) · Female Urogenital Diseases and Pregnancy Complications (27) · Genital Diseases (27) · Genital Diseases, Female (27) · Urogenital Diseases (27) · Vulvar Diseases (27) · Vaginal Diseases (26) · Bacterial Infections and Mycoses (25) · Infections (25) · Candidiasis (24) · Mycoses (24) · Vulvovaginitis (24) · Vaginitis (23) · Bacterial Infections (3)
Fluconazole (7) · ibrexafungerp (5) · Clotrimazole (3) · VT-1161 (3) · Lactulose (2) · boric acid (2) · Clindamycin (1) · Ketoconazole (1) · Natamycin (1) · Suppositories (1) · Tetracycline (1) · Vaginal Creams, Foams, and Jellies (1) · butoconazole (1) · clindamycin phosphate (1) · terconazole (1)
Scynexis, Inc. (5) · Mycovia Pharmaceuticals Inc. (3) · ProFem GmbH (2) · AVVA Pharmaceuticals Ltd. (1) · Assiut University (1) · Avva Rus, JSC (1) · Bayer (1) · Ege University (1) · Indian Council of Medical Research (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Lumara Health, Inc. (1) · Maastricht University Medical Center (1) · Medinova AG (1) · Merck Sharp & Dohme LLC (1) · Min-Tze LIONG (1)
United States (10) · Russia (4) · Austria (3) · India (3) · Germany (2) · Netherlands (2) · Belarus (1) · Bulgaria (1) · China (1) · France (1) · Ghana (1) · Guinea (1) · Japan (1) · Malaysia (1) · Pakistan (1)
David Angulo, MD (1) · Herbert Kiss, Ao.Univ.Prof.Dr. (1) · Herbert Kiss, Prof. (1) · Jacob Bornstein, MD (1) · Jacques Pepin, MD (1) · Jim Joffrion (1) · Lori Tierney (1) · Nkechi Azie, MD (1) · Ravinder Goswami, DM (1) · Sumita Bhatia, MD (1)
PMID 36396498, PMID 36255448, PMID 38319878, PMID 17128343, PMID 25887336, PMID 35943448, PMID 37640455, PMID 39979898, PMID 40970688, PMID 41845293
2008 (1), 2017 (1)